Lupin & Medicis enter into joint development agreement

Lupin Limited announced that it has entered into a research and development agreement with Medicis Pharmaceutical Corporation (“Medicis”) to apply proprietary Lupin formulation technologies to multiple therapeutic compounds.
  • Language
  • App
  • Subscriptions
  • Specials
  • Sign-In
  • Register
GeStepAhead GrowMyMoney IThe Winning Leap SME Special
Moneycontrol

Home » News » Press Release

Jul 25, 2011, 04.47 PM | Source: Moneycontrol.com

Lupin & Medicis enter into joint development agreement

Lupin Limited announced that it has entered into a research and development agreement with Medicis Pharmaceutical Corporation (“Medicis”) to apply proprietary Lupin formulation technologies to multiple therapeutic compounds.

Like this story, share it with millions of investors on M3

Lupin & Medicis enter into joint development agreement

Lupin Limited announced that it has entered into a research and development agreement with Medicis Pharmaceutical Corporation (“Medicis”) to apply proprietary Lupin formulation technologies to multiple therapeutic compounds.

Post Your Comments

Share Cancel

Lupin & Medicis enter into joint development agreement

Lupin Limited announced today that it has entered into a research and development agreement with Medicis Pharmaceutical Corporation (“Medicis”) to apply proprietary Lupin formulation technologies to multiple therapeutic compounds.

                                                                                                                       

Under the terms of the agreement, Lupin will receive a $20 million upfront payment from Medicis and will be primarily responsible for formulating certain novel therapeutic products for Medicis, utilizing several of Lupin’s formulation technologies. Medicis will have global exclusive rights (excluding India) for the products developed under the agreement. Lupin will be eligible for future research, development, regulatory and other milestones of up to $38 million, as well as a single digit royalty on sales by Medicis. Medicis will be responsible for further development and commercialization of the licensed products.

 

“We are very pleased to enter into this important collaboration with Medicis” said Nilesh Gupta, Group President and Executive Director of Lupin Limited. “This further substantiates our drug delivery capabilities in building and developing proprietary products.”

Buy, Hold, Sell ? Hear it first on M3
Lupin & Medicis enter into joint development agreement

See all

Get started using your favorite social network

or

Login using moneycontrol ID

Username
Password

Need help logging in? Reset password.

Don´t have an account? Sign Up

Get started using your favorite social network

or

Simply sign up using this short form

* mandatory

UserName*

Username should be atleast 4 character

Password*

Password should be 8 or more characters,
atleast 1 number, 1 symbol & 1 upper case letter

Alert

Your Password should contain
  • 8 or more characters
  • At least 1 number
  • At least 1 symbol
  • At least 1 upper case letter
Confirm Password*
Email
Already have an account? Login